
==== Front
ACS OmegaACS OmegaaoacsodfACS Omega2470-1343American Chemical Society 3002384510.1021/acsomega.8b00179ArticleSynthesis of TMPA Derivatives
through Sequential Ir(III)-Catalyzed
C–H Alkylation and Their Antidiabetic Evaluation Lee Suk Hun †∥Kundu Amit †∥Han Sang Hoon †Mishra Neeraj Kumar †Kim Kyeong Seok †Choi Myung Hoon ‡Pandey Ashok Kumar †Park Jung Su *§Kim Hyung Sik *†Kim In Su *†† School
of Pharmacy, Sungkyunkwan University, Seobu-ro, Jangan-gu, Suwon 16419, Republic
of Korea‡ College
of Pharmacy, Catholic University of Daegu, Hayang-ro, Hayang-eup, Gyeongsan 38430, Republic
of Korea§ Department
of Chemistry, Sookmyung Women’s University, Cheongpa-ro, Yongsan-gu, Seoul 04310, Republic
of Korea* E-mail: jspark@sookmyung.ac.kr (J.S.P.).* E-mail: hkims@skku.edu (H.S.K.).* E-mail: insukim@skku.edu (I.S.K.).06 03 2018 31 03 2018 3 3 2661 2672 29 01 2018 22 02 2018 Copyright © 2018 American Chemical
Society2018American Chemical
SocietyThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

The synthesis and antidiabetic evaluation
of ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)phenyl]acetate
(TMPA) and its structural analogs are described. The construction
of TMPA derivatives has been successfully achieved in only two steps,
which involve the iridium(III)-catalyzed α-alkylation of acetophenones
with alcohols and the ketone-directed iridium(III)- or rhodium(III)-catalyzed
redox-neutral C–H alkylation of α-alkylated acetophenones
using Meldrum’s diazo compounds. This synthetic protocol efficiently
provides a range of TMPA derivatives with site selectivity and functional
group compatibility. In addition, the site-selective demethylation
of TMPA derivative affords the naturally occurring phomopsin C in
good yield. Moreover, all synthetic compounds were screened for in
vitro adenosine 5′-monophosphate-activated protein kinase (AMPK)
activation using HepG2 cells. Furthermore, TMPA (5ac)
and 5cd showing the most potent AMPK activation were
treated for the in vivo antidiabetic experiment. Notably, our synthetic
compound 5cd was found to display the powerful antidiabetic
effect, stronger than that of metformin and TMPA (5ac).

document-id-old-9ao8b00179document-id-new-14ao-2018-00179qccc-price
==== Body
Introduction
Antidiabetic medication
has revolutionized the treatment of metabolic
disorders derived from high blood sugar level.1 For example, the use of antidiabetics such as glucagon-like peptide
agonists, KATP channel inhibitors, adenosine
5′-monophosphate-activated protein kinase (AMPK) signaling
activators, α-glucosidase inhibitors, and PPAR-γ inhibitors
has received considerable attention as potential medicinal agents.2 In particular, metformin has become the most
frequently prescribed agent for the treatment of decreasing insulin
resistance via AMPK signaling enhancement.3 In 2000, natural octaketide metabolites, cytosporones A and B, were
isolated from the broth of two endophytic fungi, Cytospora sp. CR200 and Diaporthe sp. CR146
(Figure 1).4 Notably, cytosporone B has been demonstrated
to directly interact with ligand-binding domain of nuclear orphan
receptor 77 (Nur77), which can stimulate the control of LKB1-mediated
AMPK activation.5 Additionally, unnatural
ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)phenyl]acetate (TMPA) was
also found to enhance the AMPK phosphorylation through blocking the
Nur77–LKB1 interaction.6

Figure 1 Structure of
antidiabetic octaketide metabolites.

Despite the potent antidiabetic activity and relatively simple
structure of TMPA, two synthetic strategies have been reported for
the preparation of TMPA.6 In 2012, Wu reported
the multistep synthesis of TMPA in the longest linear 7 steps including
Friedel–Craft intramolecular acylation, OsO4-mediated
dihydroxylation, and Pinnick oxidation.6a Very recently, Seo demonstrated the short synthesis of TMPA based
on the Lewis acid-mediated Friedel–Craft alkylation with ethyl
chloro(methylthio)acetate followed by reductive desulfurization.6b

Recently, the catalytic C–H functionalization
has been recognized
as a mild and economical route for the synthesis of biologically relevant
organic molecules.7 Because of the pioneering
work on the catalytic carbenoid insertion reaction toward the C–H
functionalization reported by Yu,8 the
directing group-assisted C(sp2)–H functionalization
using diazo compounds has been intensively studied for C–H
alkylation and heterocycle formation.9 Particularly,
Meldrum’s diazo compounds were also utilized as a new class
of α-diazo agents to afford the corresponding alkylated and/or
cyclized adducts.10 In continuation of
our recent studies on the biologically active compounds based on catalytic
C–H functionalization,11 we herein
disclose the iridium(III)-catalyzed α-alkylation of acetophenones
with alcohols followed by the ketone-directed Ir(III)- and Rh(III)-catalyzed ortho-C–H alkylation of acetophenones with Meldrum’s
diazo esters. As a result, this protocol may be beneficial to guide
the design of a variety of antidiabetic TMPA derivatives and represents
a catalytic alternative to transcend the barriers imposed by a previous
multistep synthetic approach.

Results and Discussion
The synthesis
of TMPA derivatives was initiated by the formation
of α-alkylated acetophenones. Acetophenone 1a was
first coupled with primary alcohols 2a–2d to provide
the α-alkylated acetophenones 3aa–3ad in
moderate yields under Ir(III) catalysis (Scheme 1).12 Moreover,
this method has been further applied to a range of acetophenones 1b–1e containing methoxy groups at the ortho-, meta-,
and para-positions, furnishing the corresponding products (3ba–3bd, 3ca–3cd, 3da–3dd, and 3ea–3ed) in moderate to high yields.

Scheme 1 Synthesis of α-Alkylated
Acetophenones
Meanwhile, the ketone-directed
iridium(III)-catalyzed orthoalkylation
of acetophenone 3aa with Meldrum’s diazo ester 4a as a model substrate was performed, as shown in Table 1. No coupling reaction
between 3aa and 4a under cationic Ir(III)
catalysis in the presence of EtOH solvent was observed (Table 1, entry 1). Interestingly, when
EtOH was subjected as an additive in DCE solvent, our desired orthoalkylated
product 5aa was obtained in 22% yield (Table 1, entry 2). To our delight,
the treatment of NaOAc as an acetate source was found to be more effective
in this transformation (Table 1, entry 3). Notably, AgOAc additive was found to be very crucial
for the high level of conversion in this reaction to afford our desired
product 5aa in 71% yield (Table 1, entries 4–7). In addition, AgSbF6 and AgPF6 as counter anions were found to be less
effective (Table 1,
entries 8 and 9). Moreover, other cationic transition-metal catalysts
such as Rh(III), Co(III), and Ru(II) were found to be ineffective
in this coupling reaction (Table 1, entries 10–12). Solvent screening revealed
that DCE is superior to other solvents such as THF, MeCN, and toluene
(Table 1, entries 13–15).
It should be noted that the reaction temperature is highly important
for the alkylation reaction to furnish 5aa in high yield
(Table 1, entries 16
and 17). Finally, this reaction provided no formation of our desired
product 5aa in the EtOH solvent (Table 1, entry 18).

Table 1 Selected
Optimization of Reaction
Conditionsa
entry	catalyst (mol %)	additive (mol %)	solvent	yield (%)b	
1	[IrCp*Cl2]2 (2)	AgNTf2 (8)	EtOH	N.R.	
2	[IrCp*Cl2]2 (2)	AgNTf2 (8), EtOH (2 equiv)	DCE	22	
3	[IrCp*Cl2]2 (2)	AgNTf2 (8), NaOAc (8 mol %), EtOH (2 equiv)	DCE	42	
4	[IrCp*Cl2]2 (2)	AgNTf2 (8), CsOAc (8 mol %), EtOH (2 equiv)	DCE	59	
5	[IrCp*Cl2]2 (2)	AgNTf2 (8), LiOAc (8 mol %), EtOH (2 equiv)	DCE	N.R.	
6	[IrCp*Cl2]2 (2)	AgNTf2 (8), Cu(OAc)2 (8 mol %), EtOH (2 equiv)	DCE	64	
7	[IrCp*Cl2]2(2)	AgNTf2(8), AgOAc(8 mol %),EtOH(2 equiv)	DCE	71	
8	[IrCp*Cl2]2 (2)	AgSbF6 (8), AgOAc (8 mol %), EtOH (2 equiv)	DCE	62	
9	[IrCp*Cl2]2 (2)	AgPF6 (8), AgOAc (8 mol %), EtOH (2 equiv)	DCE	43	
10	[RhCp*Cl2]2 (2)	AgSbF6 (8), AgOAc (8 mol %), EtOH (2 equiv)	DCE	8	
11	[CoCp*(CO)I2]
(5)	AgNTf2 (10),
AgOAc (8 mol %), EtOH (2 equiv)	DCE	N.R.	
12	[Ru(p-cymene)Cl2]2 (5)	AgNTf2 (10),
AgOAc (8 mol %), EtOH (2 equiv)	DCE	N.R.	
13	[IrCp*Cl2]2 (2)	AgNTf2 (8), AgOAc (8 mol %), EtOH (2 equiv)	THF	trace	
14	[IrCp*Cl2]2 (2)	AgNTf2 (8), AgOAc (8 mol %), EtOH (2 equiv)	MeCN	N.R.	
15	[IrCp*Cl2]2 (2)	AgNTf2 (8), AgOAc (8 mol %), EtOH (2 equiv)	toluene	trace	
16c	[IrCp*Cl2]2 (2)	AgNTf2 (8), AgOAc (8 mol %), EtOH (2 equiv)	DCE	53	
17d	[IrCp*Cl2]2 (2)	AgNTf2 (8), AgOAc (8 mol %), EtOH (2 equiv)	DCE	N.R.	
18	[IrCp*Cl2]2 (2)	AgNTf2 (8), AgOAc (8 mol %)	EtOH	N.R.	
a Reaction conditions: 3aa (0.2 mmol), 4a (0.24 mmol), catalyst (quantity noted),
additive (quantity noted), and solvent (1 mL) under air at 60 °C
for 20 h in pressure tubes.

b Isolated yield by flash column chromatography.

c The reaction was carried out at
100 °C.

d The reaction
was carried out at
room temperature.

With the
optimal reaction condition in hand, a variety of α-alkylated
acetophenones 3ab–3ed were coupled with Meldrum’s
diazo ester 4a (Scheme 2). To our pleasure, ketides 3ab–3ad were found to display good reactivity, furnishing the ortho-alkylated
TMPA derivatives 5ab–5ad. Notably, TMPA (5ac) was prepared from 1a in two steps in the
overall 31% yield via the Ir(III)-catalyzed C(sp3)–H
alkylation of 1a with primary alcohol 2c followed by subsequent Ir(III)-catalyzed ortho-C(sp2)–H
alkylation using Meldrum’s diazo ester. However, in case of
ortho-substituted acetophenone 3ba, the significantly
decreased formation of our desired product 5ba was observed.
Additionally, 2,4-dimethoxy-substituted acetophenone 3ca did not provide any coupling product under the current reaction
conditions. Thus, we further screened the reaction conditions to achieve
the site-selective alkylation between 3ba and 4a. Surprisingly, a cationic Rh(III) catalyst under the otherwise identical
reaction conditions was found to be more effective to deliver our
desired product 5ba in good yield (86%). The modified
reaction conditions can be applied to ortho-substituted acetophenones 3bb–3bd and 3ca–3cd to generate
the corresponding products in moderate to good yields. In addition,
para-methoxy-substituted acetophenones 3da–3dd were found to be coupled with 4a under Ir(III) catalysis
to provide the desired products 5da–5dd in moderate
yields. Furthermore, meta-methoxy-substituted acetophenones 3ea–3ed afforded a mixture of regioisomers 5ea–5ed and 5ea′–5ed′ at the C-6 and C-2
positions with ab. 1:2 ratio. These results that suggest the formation
of the cyclorhodated intermediate might be mainly dominated by the
electronic effect instead of the steric effect.

Scheme 2 Synthesis of TMPA
Derivatives
After successfully
screening the substrate scope of α-alkylated
acetophenones with Meldrum’s diazo ester, we envisioned that
alcohols can be also used for the derivatization of ester moiety on
TMPA. With this hypothesis, we performed the reaction of TMPA precursor 3ac with Meldrum’s diazo ester 4a in the
presence of MeOH under the otherwise identical reaction conditions
to give the methyl ester 6aa formed in 39% yield (Scheme 3). This protocol
can be successfully applied to other alcohols to afford the corresponding
ester derivatives 6ab–6ad in 56–65% yields.

Scheme 3 Derivatization of Ester Moiety on TMPA
To demonstrate the utility of synthesized orthoalkylated
acetophenones,
we first performed the site-selective demethylation of 5cc using BBr3 (4 equiv) in CH2Cl2 at
0 °C, leading to access the phomopsin C (7a) in
76% yield, which was isolated from the mangrove endophytic fungus, Phomopsis sp. ZSU-H76 (Scheme 4).13 In the meanwhile,
basic hydrolysis of ester moiety on 5cc was attempted
to afford carboxylic acid 7b in high yield. Additionally,
we also performed the construction of 3-isochromanone 7c, which is known to be a crucial synthetic intermediate in organic
synthesis, via reduction of ketone using NaBH4, followed
by subsequent intramolecular cyclization.

Scheme 4 Transformations of
TMPA Derivative 5cc
To recognize the formation of ortho-substituted acetophenone
using
Meldrum’s diazo ester, the mechanistic investigations were
subjected, as shown in Scheme 5. First, the treatment of 3ab with 4a in the absence of EtOH provided the C–H alkylated compound 8ab in 68% yield, which was further transformed into 5ab (88%) in EtOH solvent at 60 °C.14 These results support that compound 8ab is
a crucial intermediate in this process.

Scheme 5 Mechanistic Investigation
via the Isolation of Intermediate 8ab
On the basis of the above mechanistic investigations
and preceding
literature studies on the Ir(III)- or Rh(III)-catalyzed C–H
alkylations using Meldrum’s diazo esters,9f,10b a plausible reaction mechanism is outlined in Scheme 6. Initially, acetophenones 3 can undergo C–H activation with a cationic Ir(III) or Rh(III)
species to generate a metallacycle intermediate A. Subsequently,
the coordination of Meldrum’s diazo ester 4a followed
by the release of N2 gas affords a metal–carbenoid
intermediate B. Migratory insertion can deliver a 6-membered
metallacycle species C, which takes place at the protonation
process to deliver the C–H alkylated compound 8 and an active catalyst. Finally, transesterification of 8 with EtOH provides our desired product 5.

Scheme 6 Proposed
Reaction Mechanism
AMPK has been known as a major cellular regulator of glucose
and
lipid metabolism in eukaryotes, and AMPK can be automatically activated
when intracellular ATP levels are lower.15 The effect of AMPK activation is related to the enhancement of insulin
sensitivity through the increase of glucose uptake and lipid oxidation
in skeletal muscle as well as inhibition of the formation of glucose
and lipid in the liver.16 Therefore, AMPK
is a key molecule in controlling metabolic diseases such as type 2
diabetes mellitus, obesity, and cancer.

On the basis of the
previously reported data on the indirect AMPK
activation of cytosporones and TMPA,5,6 we have first
evaluated the in vitro AMPK activation against our synthetic TMPA
derivatives. In this experiment, HepG2 cells were treated with the
synthesized compounds and the phosphorylated AMPK (p-AMPK) expression
level was determined by the western blotting analysis. The potency
of compounds on AMPK activation was compared with a vehicle control
and represented as the relative percent value, as shown in Figure 2. A well-known AMPK
activator metformin was selected as a positive control. A range of
compounds (5ac, 5bd, 5cd, 5dd, 6ac, and 6ad) exhibited comparable
activity with metformin. In particular, TMPA (5ac) and 5cd were found to display the most potent AMPK activation,
stronger than that of a positive control. Notably, compound 5cd was found to be a novel AMPK activator. The structure–activity
relationship (SAR) between 5bd, 5cd, and 5dd indicates that the length of α-alkyl chain on acetophenone,
and the position of aromatic OMe-substituents play an important role
for the activation of AMPK. In addition, the ethyl carboxylate functionality
on TMPA (5ac) is found to be very crucial for AMPK activation,
which was observed by the comparison with compounds 6aa–6ad.

Figure 2 Effect of synthetic compounds on AMPK activation in HepG2 cells.
The bars represent the percentage of relative densitometric values
compared with the vehicle control.

On the basis of in vitro assay results on AMPK activation,
we further
performed in vivo antidiabetic evaluation of TMPA (5ac) and 5cd using streptozotocin (STZ)-induced diabetic
animal models (Figure 3). Interestingly, TMPA (5ac) was found to gradually
reduce the blood glucose level, which showed a comparable effect with
metformin. Moreover, our synthetic derivative 5cd exhibited
the most potent antidiabetic effect, which is about 13% stronger than
that of metformin.

Figure 3 Antidiabetic evaluation of 5ac and 5cd using type 2 diabetes-induced animal models.

Conclusions
In conclusion, we described
the efficient synthesis of TMPA derivatives
via the iridium(III)-catalyzed α-alkylation of acetophenones
with alcohols and the ketone-directed iridium(III)- or rhodium(III)-catalyzed
redox-neutral C–H alkylation of acetophenones using Meldrum’s
diazo compounds. This transformation efficiently provides an array
of orthoalkylated acetophenones with site selectivity and functional
group compatibility. In addition, all synthetic compounds were evaluated
for in vitro AMPK activation using HepG2 cells. Notably, a novel synthetic
compound 5cd was found to exhibit the stronger AMPK activation
effect than metformin. The SAR indicates that the length of α-alkyl
chain on acetophenone and the position of aromatic OMe substituents
play an important role for the AMPK activation and antidiabetic effect.
Furthermore, selected compounds TMPA (5ac) and 5cd showing the most potent AMPK activation were subjected
for the in vivo antidiabetic experiment. Interestingly, our synthetic
derivative 5cd exhibited the most potent antidiabetic
effect, which is about 13% stronger than metformin.

Experimental
Section
General Procedure for the Synthesis of α-Alkylated Acetophenones
(3aa–3ed)
To an oven-dried sealed tube
charged with 1-(3,4,5-trimethoxyphenyl)ethan-1-one (1a) (1.1 g, 5 mmol, 100 mol %), [IrCp*Cl2]2 (39.8
mg, 0.05 mmol, 1 mol %), and NaOH pellets (0.2 g, 5 mmol, 100 mol
%) were added n-butyl alcohol (2a) (0.41
g, 5.5 mmol, 110 mol %) and toluene (0.5 mL) under air at room temperature.
The reaction mixture was allowed to stir for 17 h at 110 °C.
The reaction mixture was cooled to room temperature and extracted
with EtOAc (2 × 15 mL). The organic layer was washed with brine
solution (2 × 60 mL), dried over MgSO4, filtered,
and concentrated in vacuo. The residue was purified by flash column
chromatography (n-hexanes/EtOAc = 20:1) to afford 3aa (0.67 g, 50%) as a yellowish oil.

1-(3,4,5-Trimethoxyphenyl)hexan-1-one
(3aa)
0.67 g (50%); yellowish oil; 1H NMR (400 MHz, CDCl3): δ 7.21 (s, 2H), 3.92 (s,
6H), 3.91 (s, 3H), 2.92
(t, J = 7.2 Hz, 2H), 1.76–1.70 (m, 2H), 1.38–1.34
(m, 4H), 0.91 (t, J = 6.4 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 199.3, 153.0,
142.4, 132.4, 105.6, 60.9, 56.3, 38.3, 31.5, 24.2, 22.5, 13.9; IR
(KBr) ν: 2933, 2871, 1679, 1583, 1504, 1455, 1411, 1329, 1230,
1158, 1123, 1003, 865, 824 cm–1; HRMS (quadrupole,
EI): calcd for C15H22O4 [M]+, 266.1518; found, 266.1516.

1-(3,4,5-Trimethoxyphenyl)heptan-1-one
(3ab)
0.69 g (49%); yellowish oil; 1H NMR (400 MHz, CDCl3): δ 7.21 2 (s, 2H), 3.92 (s,
6H), 3.91 (s, 3H), 2.92
(t, J = 7.2 Hz, 2H), 1.76–1.69 (m, 2H), 1.40–1.30
(m, 6H), 0.89 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 199.3, 153.0,
142.4, 132.4, 105.5, 60.9, 56.3, 38.4, 31.6, 29.0, 24.5, 22.5, 14.0;
IR (KBr) ν: 2931, 2587, 1679, 1583, 1504, 1455, 1411, 1321,
1229, 1156, 1123, 1003, 854, 831 cm–1; HRMS (quadrupole,
EI): calcd for C16H24O4 [M]+, 280.1675; found, 280.1678.

1-(3,4,5-Trimethoxyphenyl)octan-1-one
(3ac)
0.76 g (52%); yellowish oil; 1H NMR (400 MHz, CDCl3): δ 7.21 (s, 2H), 3.92 (s,
6H), 3.91 (s, 3H), 2.92
(t, J = 7.2 Hz, 2H), 1.76–1.69 (m, 2H), 1.37–1.27
(m, 8H), 0.88 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 199.3, 153.0,
142.4, 132.4, 105.5, 60.9, 56.3, 38.3, 31.7, 29.3, 29.1, 24.5, 22.6,
14.0; IR (KBr) ν: 2926, 2854, 1678, 1583, 1504, 1455, 1411,
1322, 1230, 1156, 1123, 1004, 859, 823 cm–1; HRMS
(quadrupole, EI): calcd for C17H26O4 [M]+, 294.1831; found, 294.1833.

1-(3,4,5-Trimethoxyphenyl)nonan-1-one
(3ad)
0.77 g (50%); yellowish oil; 1H NMR (400 MHz, CDCl3): δ 7.21 (s, 2H), 3.92 (s,
6H), 3.91 (s, 3H), 2.92
(t, J = 7.2 Hz, 2H), 1.74–1.69 (m, 2H), 1.38–1.27
(m, 10H), 0.88 (t, J = 6.4 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 199.3,
153.0, 142.4, 132.4, 105.5, 60.9, 56.3, 38.4, 31.8, 29.4, 29.1, 24.5,
22.6, 14.1; IR (KBr) ν: 2925, 2853, 1679, 1583, 1504, 1455,
1411, 1322, 1230, 1155, 1124, 1004, 854, 829 cm–1; HRMS (quadrupole, EI): calcd for C18H28O4 [M]+, 308.1988; found, 308.1987.

1-(2-Methoxyphenyl)hexan-1-one
(3ba)
0.54
g (52%); light brown oil; 1H NMR (400 MHz, CDCl3): δ 7.64 (d, J = 7.6 Hz, 1H), 7.43 (t, J = 7.6 Hz, 1H), 6.99 (t, J = 7.2 Hz, 1H),
6.95 (d, J = 8.4 Hz, 1H), 3.89 (s, 3H), 2.95 (t, J = 7.2 Hz, 2H), 1.69–1.63 (m, 2H), 1.36–1.30
(m, 4H), 0.89 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 203.3, 158.2,
133.0, 130.1, 128.8, 120.6, 111.4, 55.4, 43.7, 31.6, 24.1, 22.5, 14.0;
IR (KBr) ν: 2955, 2929, 2860, 1673, 1597, 1485, 1464, 1436,
1282, 1243, 1180, 1162, 1023, 754 cm–1; HRMS (quadrupole,
EI): calcd for C13H18O2 [M]+, 206.1307; found, 206.1305.

1-(2-Methoxyphenyl)heptan-1-one
(3bb)
0.72 g (65%); light brown oil; 1H NMR (400 MHz, CDCl3): δ 7.63 (dd, J = 7.6, 1.6 Hz, 1H),
7.45–7.41 (m, 1H), 6.99 (td, J = 8.4, 1.0
Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 3.89 (s, 3H),
2.95 (t, J = 7.2 Hz, 2H), 1.70–1.62 (m, 2H),
1.37–1.27 (m, 6H), 0.88 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ
203.4, 158.3, 133.0, 130.1, 128.9, 120.6, 111.4, 55.4, 43.8, 31.7,
29.1, 24.4, 22.5, 14.0; IR (KBr) ν: 2954, 2927, 2857, 1472,
1597, 1484, 1464, 1436, 1284, 1241, 1180, 1162, 1023, 753 cm–1; HRMS (quadrupole, EI): calcd for C14H20O2 [M]+, 220.1463; found, 220.1464.

1-(2-Methoxyphenyl)octan-1-one
(3bc)
0.66
g (56%); yellowish oil; 1H NMR (400 MHz, CDCl3): δ 7.62 (dd, J = 7.6, 2.0 Hz, 1H), 7.45–7.41
(m, 1H), 6.98 (td, J = 8.4, 1.0 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 3.89 (s, 3H), 2.94 (t, J = 7.6 Hz, 2H), 1.70–1.62 (m, 2H), 1.35–1.26 (m, 8H),
0.87 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 203.4, 158.2, 133.0,
130.1, 128.8, 120.6, 111.4, 55.4, 43.7, 31.7, 29.3, 29.1, 24.4, 22.6,
14.0; IR (KBr) ν: 2953, 2925, 2854, 1673, 1597, 1484, 1464,
1436, 1283, 1242, 1179, 1161, 1024, 753 cm–1; HRMS
(quadrupole, EI): calcd for C15H22O2 [M]+, 234.1620; found, 234.1621.

1-(2-Methoxyphenyl)nonan-1-one
(3bd)
0.62
g (50%); yellowish oil; 1H NMR (400 MHz, CDCl3): δ 7.63 (dd, J = 8.0, 2.0 Hz, 1H), 7.45–7.41
(m, 1H), 6.99 (td, J = 8.4, 1.0 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 3.89 (s, 3H), 2.94 (t, J = 7.2 Hz, 2H), 1.70–1.62 (m, 2H), 1.35–1.26 (m, 10H),
0.87 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 203.4, 158.2, 133.0,
130.1, 128.8, 120.6, 111.4, 55.4, 43.8, 31.8, 29.5, 29.4, 29.2, 24.4,
22.6, 14.1; IR (KBr) ν: 2924, 2853, 1673, 1597, 1484, 1464,
1436, 1283, 1242, 1180, 1162, 1024, 753 cm–1; HRMS
(quadrupole, EI): calcd for C16H24O2 [M]+, 248.1776; found, 248.1773.

1-(2,4-Dimethoxyphenyl)hexan-1-one
(3ca)
0.58 g (49%); yellowish oil; 1H NMR (400 MHz, CDCl3): δ 7.77 (d, J = 8.8 Hz, 1H), 6.51
(dd, J = 8.8, 2.0 Hz, 1H), 6.44 (d, J = 2.4 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 2.91 (t, J = 7.6 Hz, 2H), 1.69–1.62 (m, 2H), 1.36–1.30 (m, 4H),
0.89 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 201.0, 164.1, 160.5,
132.6, 121.5, 104.9, 98.4, 55.5, 55.4, 43.6, 31.7, 24.3, 22.5, 14.0;
IR (KBr) ν: 2954, 2931, 2859, 1662, 1598, 1573, 1463, 1416,
1253, 1210, 1161, 1130, 1103, 1027, 826 cm–1; HRMS
(quadrupole, EI): calcd for C14H20O3 [M]+, 236.1412; found, 236.1413.

1-(2,4-Dimethoxyphenyl)heptan-1-one
(3cb)
0.71 g (57%); yellowish oil; 1H NMR (400 MHz, CDCl3): δ 7.77 (d, J = 8.0 Hz, 1H), 6.51
(dd, J = 8.0, 4.0 Hz, 1H), 6.44 (d, J = 4.0 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 2.91 (t, J = 8.0 Hz, 2H), 1.68–1.61 (m, 2H), 1.37–1.30 (m, 6H),
0.88 (t, J = 8.0 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 201.0, 164.1, 160.5,
132.5, 121.5, 104.9, 98.3, 55.5, 55.4, 43.6, 31.7, 29.2, 24.6, 22.5,
14.0; IR (KBr) ν: 2953, 2926, 2855, 1662, 1598, 1574, 1463,
1416, 1253, 1209, 1161, 1130, 1027, 834 cm–1; HRMS
(quadrupole, EI): calcd for C15H22O3 [M]+, 250.1569; found, 250.1568.

1-(2,4-Dimethoxyphenyl)octan-1-one
(3cc)
0.71 g (54%); yellowish oil; 1H NMR (400 MHz, CDCl3): δ 7.77 (d, J = 8.8 Hz, 1H), 6.51
(dd, J = 8.4, 2.0 Hz, 1H), 6.44 (d, J = 2.4 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 2.91 (t, J = 7.2 Hz, 2H), 1.68–1.61 (m, 2H), 1.33–1.26 (m, 8H),
0.87 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 201.0, 164.1, 160.5,
132.5, 121.5, 104.9, 98.4, 55.5, 55.4, 43.6, 31.7, 29.4, 29.2, 24.6,
22.6, 14.1; IR (KBr) ν: 2925, 2854, 1663, 1598, 1574, 1463,
1416, 1254, 1209, 1161, 1130, 1027, 834 cm–1; HRMS
(quadrupole, EI): calcd for C16H24O3 [M]+, 264.1725; found, 264.1725.

1-(2,4-Dimethoxyphenyl)nonan-1-one
(3cd)
0.74 g (53%); yellowish oil; 1H NMR (400 MHz, CDCl3): δ 7.77 (d, J = 8.0 Hz, 1H), 6.51
(dd, J = 8.8, 1.6 Hz, 1H), 6.44 (d, J = 2.0 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 2.91 (t, J = 7.6 Hz, 2H), 1.68–1.61 (m, 2H), 1.34–1.26 (m, 10H),
0.87 (t, J = 6.0 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 201.0, 164.1, 160.5,
132.5, 121.5, 104.9, 98.3, 55.5, 55.4, 43.6, 31.8, 29.5, 29.2, 24.6,
22.6, 14.1; IR (KBr) ν: 2924, 2853, 1663, 1598, 1574, 1463,
1416, 1254, 1209, 1161, 1028, 834 cm–1; HRMS (quadrupole,
EI): calcd for C17H26O3 [M]+, 278.1882; found, 278.1881.

1-(4-Methoxyphenyl)hexan-1-one
(3da)
0.57
g (55%); white solid; mp = 42.4–44.1 °C; 1H
NMR (400 MHz, CDCl3): δ 7.95–7.92 (m, 2H),
6.94–6.91 (m, 2H), 3.86 (s, 3H), 2.90 (t, J = 7.6 Hz, 2H), 1.76–1.68 (m, 2H), 1.37–1.33 (m, 4H),
0.90 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 199.2, 163.3, 130.3,
130.2, 113.6, 55.4, 38.3, 31.6, 24.3, 22.5, 13.9; IR (KBr) ν:
2955, 2931, 2860, 1674, 1597, 1509, 1461, 1417, 1308, 1252, 1168,
1030, 828 cm–1; HRMS (quadrupole, EI): calcd for
C13H18O2 [M]+, 206.1307;
found, 206.1305.

1-(4-Methoxyphenyl)heptan-1-one (3db)
0.90 g (82%); white solid; mp = 44.2–46.7 °C; 1H NMR (400 MHz, CDCl3): δ 7.96–7.92
(m, 2H),
6.95–6.90 (m, 2H), 3.86 (s, 3H), 2.90 (t, J = 7.6 Hz, 2H), 1.75–1.67 (m, 2H), 1.40–1.29 (m, 6H),
0.88 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 199.2, 163.3, 130.3,
130.2, 113.6, 55.4, 38.3, 31.6, 29.1, 24.6, 22.5, 14.0; IR (KBr) ν:
2954, 2929, 2856, 1675, 1597, 1509, 1460, 1417, 1308, 1255, 1467,
1029, 835 cm–1; HRMS (quadrupole, EI): calcd for
C14H20O2 [M]+, 220.1463;
found, 220.1460.

1-(4-Methoxyphenyl)octan-1-one (3dc)
0.99
g (84%); white solid; mp = 53.2–55.9 °C; 1H
NMR (400 MHz, CDCl3): δ 7.94 (dt, J = 10.0, 3.2 Hz, 2H), 6.92 (dt, J = 9.6, 2.8 Hz,
2H), 3.86 (s, 3H), 2.90 (t, J = 7.2 Hz, 2H), 1.75–1.68
(m, 2H), 1.37–1.27 (m, 8H), 0.88 (t, J = 6.8
Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 199.2, 163.2, 130.3, 130.2, 113.6, 55.4, 38.3, 31.7, 29.4,
29.1, 24.6, 22.6, 14.0; IR (KBr) ν: 2954, 2925, 2854, 1675,
1599, 1509, 1462, 1417, 1308, 1255, 1168, 1030, 829 cm–1; HRMS (quadrupole, EI): calcd for C15H22O2 [M]+, 234.1620; found, 234.1618.

1-(4-Methoxyphenyl)nonan-1-one
(3dd)
0.96
g (77%); white solid; mp 53.8–55.2 °C; 1H NMR
(400 MHz, CDCl3): δ 7.93 (dt, J =
9.6, 2.8 Hz, 2H), 6.92 (dt, J = 9.6, 2.8 Hz, 2H),
3.86 (s, 3H), 2.90 (t, J = 7.2 Hz, 2H), 1.75–1.67
(m, 2H), 1.38–1.25 (m, 10H), 0.87 (t, J =
6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 199.2, 163.2, 130.3, 130.2, 113.6, 55.4, 38.3,
31.8, 29.4, 29.1, 24.6, 22.6, 14.1; IR (KBr) ν: 2954, 2924,
2853, 1676, 1599, 1509, 1463, 1417, 1307, 1254, 1168, 1031, 833 cm–1; HRMS (quadrupole, EI): calcd for C16H24O2 [M]+, 248.1776; found, 248.1776.

1-(3-Methoxyphenyl)hexan-1-one (3ea)
0.61
g (59%); yellowish oil; 1H NMR (400 MHz, CDCl3): δ 7.53 (d, J = 7.6 Hz, 1H), 7.49 (s, 1H),
7.36 (t, J = 8.0 Hz, 1H), 7.09 (dd, J = 8.0, 2.4 Hz, 1H), 3.85 (s, 3H), 2.94 (t, J =
7.6 Hz, 2H), 1.77–1.70 (m, 2H), 1.37–1.34 (m, 4H), 0.91
(t, J = 6.8 Hz, 3H); 13C{1H}
NMR (100 MHz, CDCl3): δ 200.5, 159.9, 138.6, 129.6,
120.8, 119.4, 112.4, 55.5, 38.8, 31.6, 24.2, 22.6, 14.1; IR (KBr)
ν: 2955, 2930, 2860, 1683, 1597, 1582, 1485, 1463, 1428, 1287,
1266, 1169, 1040, 784 cm–1; HRMS (quadrupole, EI):
calcd for C13H18O2 [M]+, 206.1307; found, 206.1308.

1-(3-Methoxyphenyl)heptan-1-one
(3eb)
0.63 g (57%); yellowish oil; 1H NMR (400 MHz, CDCl3): δ 7.53 (dt, J = 7.6, 1.6 Hz, 1H),
7.49–7.48 (m, 1H), 7.36 (t, J = 8.0 Hz, 1H),
7.09 (ddd, J = 8.4, 2.8, 1.0 Hz, 1H), 3.85 (s, 3H),
2.94 (t, J = 7.2 Hz, 2H), 1.76–1.68 (m, 2H),
1.41–1.29 (m, 6H), 0.89 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ
200.4, 159.8, 138.5, 129.5, 120.7, 119.3, 112.3, 55.4, 38.7, 31.6,
29.0, 24.4, 22.5, 14.0; IR (KBr) ν: 2954, 2928, 2857, 1684,
1597, 1582, 1486, 1463, 1428, 1254, 1167, 1044, 783 cm–1; HRMS (quadrupole, EI): calcd for C14H20O2 [M]+, 220.1463; found, 220.1460.

1-(3-Methoxyphenyl)octan-1-one
(3ec)
0.65
g (55%); yellowish oil; 1H NMR (400 MHz, CDCl3): δ 7.54 (dt, J = 7.6, 1.2 Hz, 1H), 7.49–7.48
(m, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.10 (ddd, J = 8.0, 2.8, 1.0 Hz, 1H), 3.85 (s, 3H), 2.94 (t, J = 7.2 Hz, 2H), 1.76–1.69 (m, 2H), 1.39–1.27
(m, 8H), 0.88 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 200.4, 159.8,
138.5, 129.5, 120.7, 119.3, 112.3, 55.4, 38.7, 31.6, 29.3, 29.1, 24.4,
22.6, 14.1; IR (KBr) ν: 2954, 2925, 2855, 1683, 1597, 1582,
1485, 1463, 1428, 1252, 1167, 1040, 783 cm–1; HRMS
(quadrupole, EI): calcd for C15H22O2 [M]+, 234.1620; found, 234.1619.

1-(3-Methoxyphenyl)nonan-1-one
(3ed)
0.73
g (59%); light yellow oil; 1H NMR (400 MHz, CDCl3): δ 7.54 (dt, J = 7.6, 1.6 Hz, 1H), 7.49–7.48
(m, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.10 (ddd, J = 8.4, 2.8, 1.0 Hz, 1H), 3.85 (s, 3H), 2.94 (t, J = 7.2 Hz, 2H), 1.76–1.68 (m, 2H), 1.39–1.27
(m, 10H), 0.87 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 200.4,
159.8, 138.5, 129.5, 120.7, 119.3, 112.3, 55.4, 38.7, 31.8, 29.4,
29.3, 29.2, 24.4, 22.6, 14.1; IR (KBr) ν: 2954, 2924, 2853,
1683, 1597, 1582, 1486, 1463, 1428, 1259, 1166, 1043, 783 cm–1; HRMS (quadrupole, EI): calcd for C16H24O2 [M]+, 248.1776; found, 248.1775.

General
Procedure for the Synthesis of ortho-Alkylated Derivatives
(5aa–5ed′ and 6aa–6ad)
To an oven-dried sealed tube charged with 1-(3,4,5-trimethoxyphenyl)hexan-1-one
(3aa) (53.3 mg, 0.2 mmol, 100 mol %), [IrCp*Cl2]2 (3.2 mg, 0.004 mmol, 2 mol %) or [RhCp*Cl2]2 (2.5 mg, 0.004 mmol, 2 mol %), AgNTf2 (6.2
mg, 0.016 mmol, 8 mol %), AgOAc (2.6 mg, 0.016 mmol, 8 mol %), and
5-diazo-2,2-dimethyl-1,3-dioxane-4,6-dione (4a) (40.8
mg, 0.24 mmol, 120 mol %) were added EtOH (18.4 mg, 0.4 mmol, 200
mol %) and DCE (1 mL) under air at room temperature. The reaction
mixture was allowed to stir for 20 h at 60 °C. The reaction mixture
was cooled to room temperature, diluted with EtOAc (3 mL), and concentrated
in vacuo. The residue was purified by flash column chromatography
(n-hexanes/EtOAc = 12:1) to afford 5aa (50.2 mg, 71%) as a yellowish solid.

Ethyl 2-(6-Hexanoyl-2,3,4-trimethoxyphenyl)acetate
(5aa)
50.2 mg (71%); yellowish solid; mp 66.0–68.2
°C; 1H NMR (400 MHz, CDCl3): δ 7.02
(s, 1H), 4.14
(q, J = 7.2 Hz, 2H), 3.90 (s, 3H), 3.89 (s, 3H),
3.87 (s, 2H), 3.82 (s, 3H), 2.84 (t, J = 7.2 Hz,
2H), 1.70–1.62 (m, 2H), 1.33–1.28 (m, 4H), 1.25 (t, J = 7.2 Hz, 3H), 0.88 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ
202.9, 172.0, 152.7, 151.7, 145.0, 133.5, 121.7, 108.4, 61.0, 60.7,
60.5, 56.1, 40.9, 31.8, 31.4, 24.0, 22.4, 14.2, 13.8; IR (KBr) ν:
2939, 2871, 1733, 1682, 1595, 1568, 1495, 1453, 1403, 1331, 1172,
1137, 1113, 1028, 966, 918, 831 cm–1; HRMS (quadrupole,
EI): calcd for C19H28O6 [M]+, 352.1886; found, 352.1884.

Ethyl 2-(6-Heptanoyl-2,3,4-trimethoxyphenyl)acetate
(5ab)
44.9 mg (61%); yellowish oil; 1H NMR (400 MHz,
CDCl3): δ 7.02 (s, 1H), 4.13 (q, J = 7.2 Hz, 2H), 3.90 (s, 3H), 3.89 (s, 3H), 3.88 (s, 2H), 3.82 (s,
3H), 2.85 (t, J = 7.6 Hz, 2H), 1.70–1.62 (m,
2H), 1.35–1.28 (m, 6H), 1.25 (t, J = 6.8 Hz,
3H), 0.87 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 203.0, 172.0,
152.7, 151.8, 145.1, 133.6, 121.8, 108.4, 61.0, 60.7, 60.5, 56.2,
41.0, 31.8, 31.6, 28.9, 24.3, 22.4, 14.2, 13.9; IR (KBr) ν:
2933, 2857, 1735, 1683, 1593, 1568, 1495, 1454, 1403, 1335, 1230,
1174, 1138, 1116, 1029, 966, 920, 841 cm–1; HRMS
(quadrupole, EI): calcd for C20H30O6 [M]+, 366.2042; found, 366.2044.

Ethyl 2-(2,3,4-Trimethoxy-6-octanoylphenyl)acetate
(5ac)
45.1 mg (59%); yellowish oil; 1H NMR (400 MHz,
CDCl3): δ 7.02 (s, 1H), 4.13 (q, J = 7.2 Hz, 2H), 3.90 (s, 3H), 3.89 (s, 3H), 3.87 (s, 2H), 3.82 (s,
3H), 2.85 (t, J = 7.2 Hz, 2H), 1.70–1.62 (m,
2H), 1.31–1.23 (m, 11H), 0.86 (t, J = 6.4
Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 203.0, 172.0, 152.7, 151.7, 145.0, 133.5, 121.7, 108.4,
61.0, 60.7, 60.5, 56.2, 41.0, 31.8, 31.6, 29.2, 29.0, 24.3, 22.5,
14.2, 14.0; IR (KBr) ν: 2927, 2854, 1736, 1683, 1593, 1568,
1495, 1454, 1403, 1333, 1251, 1162, 1137, 1116, 1029, 1006, 966, 920,
838 cm–1; HRMS (quadrupole, EI): calcd for C21H32O6 [M]+, 380.2199; found,
380.2202.

Ethyl 2-(2,3,4-Trimethoxy-6-nonanoylphenyl)acetate
(5ad)
49.1 mg (62%); yellowish oil; 1H NMR (400 MHz,
CDCl3): δ 7.02 (s, 1H), 4.14 (q, J = 7.2 Hz, 2H), 3.90 (s, 3H), 3.89 (s, 3H), 3.87 (s, 2H), 3.82 (s,
3H), 2.84 (t, J = 7.6 Hz, 2H), 1.69–1.62 (m,
2H), 1.32–1.23 (m, 13H), 0.86 (t, J = 6.8
Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 203.0, 172.0, 152.8, 151.8, 145.1, 133.6, 121.8, 108.5,
61.0, 60.7, 60.5, 56.2, 41.0, 31.8, 31.7, 29.4, 29.2, 29.1, 24.3,
22.6, 14.2, 14.0; IR (KBr) ν: 2925, 2853, 1735, 1663, 1593,
1568, 1495, 1454, 1403, 1367, 1333, 1229, 1161, 1136, 1115, 1028,
1007, 966, 917, 838 cm–1; HRMS (quadrupole, EI):
calcd for C22H34O6 [M]+, 394.2355; found, 394.2358.

Ethyl 2-(2-Hexanoyl-3-methoxyphenyl)acetate
(5ba)
50.3 mg (86%); light yellow oil; 1H NMR (400
MHz, CDCl3): δ 7.27 (t, J = 8.0
Hz, 1H), 6.87–6.85 (m, 2H), 4.12 (q, J = 7.2
Hz, 2H), 3.81 (s, 3H), 3.59 (s, 2H), 2.84 (t, J =
7.2 Hz, 2H), 1.71–1.63 (m, 2H), 1.34–1.30 (m, 4H), 1.24
(t, J = 7.2 Hz, 3H), 0.90 (t, J =
7.2 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 207.8, 171.2, 156.7, 132.3, 131.5, 130.2, 123.2,
109.9, 60.9, 55.6, 44.4, 38.2, 31.4, 23.3, 22.5, 14.1, 13.9; IR (KBr)
ν: 2955, 2927, 2856, 1734, 1691, 1597, 1581, 1469, 1438, 1367,
1336, 1259, 1181, 1159, 1073, 1030, 950, 768 cm–1; HRMS (quadrupole, EI): calcd for C17H24O4 [M]+, 292.1675; found, 292.1675.

Ethyl 2-(2-Heptanoyl-3-methoxyphenyl)acetate
(5bb)
54.1 mg (88%); light yellow
oil; 1H NMR (400 MHz, CDCl3): δ 7.27 (t, J = 8.0 Hz, 1H), 6.87–6.83 (m, 2H), 4.12 (q, J = 6.8 Hz, 2H), 3.81 (s, 3H), 3.58 (s, 2H), 2.84 (t, J = 7.2 Hz, 2H), 1.70–1.62 (m, 2H), 1.36–1.27
(m, 6H),
1.24 (t, J = 7.2 Hz, 3H), 0.88 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 207.8, 171.2, 156.7, 132.3, 131.5, 130.2, 123.2,
109.9, 60.8, 55.5, 44.4, 38.2, 31.6, 28.9, 23.5, 22.5, 14.1, 14.0;
IR (KBr) ν: 2955, 2928, 2856, 1735, 1691, 1598, 1582, 1469,
1438, 1367, 1297, 1262, 1181, 1160, 1074, 1030, 949, 760 cm–1; HRMS (quadrupole, EI): calcd for C18H26O4 [M]+, 306.1831; found, 306.1832.

Ethyl 2-(3-Methoxy-2-octanoylphenyl)acetate
(5bc)
58.9 mg (92%); light yellow oil; 1H NMR (400
MHz, CDCl3): δ 7.27 (t, J = 8.0
Hz, 1H), 6.87–6.83 (m, 2H), 4.12 (q, J = 7.2
Hz, 2H), 3.81 (s, 3H), 3.59 (s, 2H), 2.84 (t, J =
7.6 Hz, 2H), 1.70–1.62 (m, 2H), 1.34–1.26 (m, 8H), 1.24
(t, J = 7.2 Hz, 3H), 0.88 (t, J =
6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 207.9, 171.2, 156.7, 132.3, 131.5, 130.2, 123.2,
109.9, 60.9, 55.6, 44.4, 38.2, 31.7, 29.2, 29.1, 23.6, 22.6, 14.1,
14.0; IR (KBr) ν: 2955, 2925, 2854, 1735, 1691, 1597, 1581,
1469, 1438, 1367, 1297, 1260, 1180, 1158, 1074, 1029, 952, 754 cm–1; HRMS (quadrupole, EI): calcd for C19H28O4 [M]+, 320.1988; found, 320.1987.

Ethyl 2-(3-Methoxy-2-nonanoylphenyl)acetate (5bd)
47.5 mg (71%); light yellow oil; 1H NMR (400
MHz, CDCl3): δ 7.28 (t, J = 8.0
Hz, 1H), 6.87–6.83 (m, 2H), 4.12 (q, J = 7.2
Hz, 2H), 3.81 (s, 3H), 3.59 (s, 2H), 2.84 (t, J =
7.2 Hz, 2H), 1.70–1.62 (m, 2H), 1.35–1.22 (m, 13H),
0.87 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 207.9, 171.2, 156.7,
132.3, 131.5, 130.2, 123.2, 109.9, 60.9, 55.6, 44.4, 38.2, 31.8, 29.4,
29.3, 29.2, 23.6, 22.6, 14.2, 14.1; IR (KBr) ν: 2954, 2925,
2853, 1735, 1691, 1597, 1581, 1468, 1438, 1367, 1297, 1259, 1180,
1158, 1075, 1030, 952 cm–1; HRMS (quadrupole, EI):
calcd for C20H30O4 [M]+, 334.2144; found, 334.2143.

Ethyl 2-(2-Hexanoyl-3,5-dimethoxyphenyl)acetate
(5ca)
24.5 mg (38%); yellowish oil; 1H NMR (400 MHz,
CDCl3): δ 6.38 (s, 1H), 6.37 (s, 1H), 4.12 (q, J = 7.2 Hz, 2H), 3.81 (s, 3H), 3.80 (s, 3H), 3.61 (s, 2H),
2.81 (t, J = 7.2 Hz, 2H), 1.66–1.60 (m, 2H),
1.32–1.30 (m, 4H), 1.24 (t, J = 7.2 Hz, 3H),
0.87 (t, J = 6.4 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 207.0, 171.2, 161.2,
158.7, 134.4, 124.2, 107.7, 97.5, 60.8, 55.5, 55.3, 44.4, 38.8, 31.5,
23.7, 22.5, 14.1, 13.9; IR (KBr) ν: 2955, 2929, 2857, 1734,
1682, 1601, 1580, 1457, 1423, 1315, 1290, 1254, 1202, 1152, 1084,
1029, 950, 834 cm–1; HRMS (quadrupole, EI): calcd
for C18H26O5 [M]+, 322.1780;
found, 322.1781.

Ethyl 2-(2-Heptanoyl-3,5-dimethoxyphenyl)acetate
(5cb)
30.4 mg (45%); yellowish oil; 1H NMR (400 MHz,
CDCl3): δ 6.38 (s, 1H), 6.37 (s, 1H), 4.11 (q, J = 6.8 Hz, 2H), 3.81 (s, 3H), 3.80 (s, 3H), 3.60 (s, 2H),
2.81 (t, J = 7.6 Hz, 2H), 1.67–1.59 (m, 2H),
1.35–1.29 (m, 6H), 1.24 (t, J = 7.2 Hz, 3H),
0.87 (t, J = 6.4 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 207.0, 171.2, 161.2,
158.7, 134.4, 124.2, 107.7, 97.5, 60.8, 55.5, 55.3, 44.5, 38.8, 31.7,
29.0, 24.0, 22.5, 14.1, 14.0; IR (KBr) ν: 2955, 2930, 2856,
1734, 1682, 1601, 1580, 1457, 1423, 1367, 1315, 1254, 1202, 1151,
1085, 1029, 950, 834 cm–1; HRMS (quadrupole, EI):
calcd for C19H28O5 [M]+, 336.1937; found, 336.1939.

Ethyl 2-(3,5-Dimethoxy-2-octanoylphenyl)acetate
(5cc)
33.7 mg (48%); yellowish oil; 1H NMR (400 MHz,
CDCl3): δ 6.39 (br s, 1H), 6.37 (br s, 1H), 4.13
(q, J = 8.0 Hz, 2H), 3.81 (s, 3H), 3.80 (s, 3H),
3.61 (s, 2H), 2.82 (t, J = 8.0 Hz, 2H), 1.67–1.60
(m, 2H), 1.32–1.23 (m, 11H), 0.87 (t, J =
8.0 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 207.0, 171.3, 161.2, 158.7, 134.4, 124.3, 107.7,
97.5, 60.8, 55.5, 55.4, 44.5, 38.9, 31.7, 29.3, 29.1, 24.0, 22.6,
14.2, 14.1; IR (KBr) ν: 2954, 2927, 2854, 1734, 1682, 1601,
1580, 1457, 1423, 1366, 1315, 1260, 1201, 1151, 1086, 1030, 951, 833
cm–1; HRMS (quadrupole, EI): calcd for C20H30O5 [M]+, 350.2093; found, 350.2096.

Ethyl 2-(3,5-Dimethoxy-2-nonanoylphenyl)acetate (5cd)
38.1 mg (52%); yellowish oil; 1H NMR (400 MHz,
CDCl3): δ 6.38 (s, 1H), 6.37 (s, 1H), 4.12 (q, J = 7.2 Hz, 2H), 3.80 (s, 3H), 3.79 (s, 3H), 3.60 (s, 2H),
2.81 (t, J = 7.2 Hz, 2H), 1.65–1.59 (m, 2H),
1.29–1.22 (m, 13H), 0.87 (t, J = 6.4 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ
207.0, 171.2, 161.2, 158.7, 134.4, 124.2, 107.7, 97.5, 60.8, 55.5,
55.3, 44.5, 38.8, 31.7, 29.4, 29.3, 29.1, 24.0, 22.6, 14.1, 14.0;
IR (KBr) ν: 2925, 2853, 1735, 1682, 1602, 1580, 1457, 1423,
1367, 1315, 1256, 1201, 1151, 1087, 1030, 952, 834 cm–1; HRMS (quadrupole, EI): calcd for C21H32O5 [M]+, 364.2250; found, 364.2247.

Ethyl 2-(2-Hexanoyl-5-methoxyphenyl)acetate
(5da)
24.1 mg (41%); yellowish oil; 1H NMR (400 MHz,
CDCl3): δ 7.81 (d, J = 8.8 Hz, 1H),
6.84 (dd, J = 8.4, 2.4 Hz, 1H), 6.74 (d, J = 2.4 Hz, 1H), 4.15 (q, J = 7.2 Hz, 2H),
3.91 (s, 2H), 3.85 (s, 3H), 2.88 (t, J = 7.2 Hz,
2H), 1.71–1.63 (m, 2H), 1.34–1.31 (m, 4H), 1.26 (t, J = 7.2 Hz, 3H), 0.89 (t, J = 6.4 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ
201.8, 171.5, 161.9, 137.5, 131.9, 129.7, 118.5, 111.8, 60.6, 55.3,
40.9, 40.2, 31.5, 24.3, 22.5, 14.2, 13.9; IR (KBr) ν: 2956,
2928, 2858, 1733, 1673, 1603, 1569, 1464, 1428, 1367, 1336, 1315,
1291, 1244, 1211, 1159, 1131, 1031, 977, 877 cm–1; HRMS (quadrupole, EI): calcd for C17H24O4 [M]+, 292.1675; found, 292.1674.

Ethyl 2-(2-Heptanoyl-5-methoxyphenyl)acetate
(5db)
24.5 mg (40%); yellowish oil; 1H NMR (400 MHz,
CDCl3): δ 7.81 (d, J = 8.8 Hz, 1H),
6.84 (dd, J = 8.4, 2.4 Hz, 1H), 6.74 (d, J = 2.4 Hz, 1H), 4.14 (q, J = 7.2 Hz, 2H),
3.91 (s, 2H), 3.85 (s, 3H), 2.88 (t, J = 7.2 Hz,
2H), 1.70–1.63 (m, 2H), 1.38–1.30 (m, 6H), 1.26 (t, J = 7.2 Hz, 3H), 0.88 (t, J = 6.4 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ
201.8, 171.5, 161.9, 137.5, 131.9, 129.7, 118.5, 111.8, 60.6, 55.3,
40.9, 40.3, 31.6, 29.0, 24.6, 22.5, 14.2, 14.0; IR (KBr) ν:
2955, 2929, 2856, 1734, 1673, 1603, 1569, 1464, 1367, 1336, 1315,
1291, 1255, 1230, 1208, 1159, 1131, 1031, 980, 877, 814 cm–1; HRMS (quadrupole, EI): calcd for C18H26O4 [M]+, 306.1831; found, 306.1831.

Ethyl 2-(5-Methoxy-2-octanoylphenyl)acetate
(5dc)
25.1 mg (39%); yellowish oil; 1H NMR (400 MHz,
CDCl3): δ 7.81 (d, J = 8.8 Hz, 1H),
6.84 (dd, J = 8.4, 2.4 Hz, 1H), 6.74 (d, J = 2.8 Hz, 1H), 4.15 (q, J = 7.2 Hz, 2H),
3.91 (s, 2H), 3.84 (s, 3H), 2.87 (t, J = 7.2 Hz,
2H), 1.68–1.62 (m, 2H), 1.33–1.24 (m, 11H), 0.87 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100
MHz, CDCl3): δ 201.8, 171.5, 161.9, 137.5, 131.9,
129.7, 118.5, 111.8, 60.6, 55.3, 40.9, 40.3, 31.7, 29.3, 29.1, 24.6,
22.6, 14.2, 14.1; IR (KBr) ν: 2954, 2925, 2853, 1735, 1674,
1604, 1569, 1464, 1367, 1315, 1254, 1225, 1159, 1131, 1031, 983, 877,
815 cm–1; HRMS (quadrupole, EI): calcd for C19H28O4 [M]+, 320.1988; found,
320.1987.

Ethyl 2-(5-Methoxy-2-nonanoylphenyl)acetate
(5dd)
26.8 mg (40%); white solid; mp 51.2–53.8
°C; 1H NMR (400 MHz, CDCl3): δ 7.81
(d, J = 8.8 Hz, 1H), 6.84 (dd, J = 8.8, 2.4
Hz, 1H), 6.74 (d, J = 2.4 Hz, 1H), 4.15 (q, J = 7.2 Hz, 2H), 3.91 (s, 2H), 3.84 (s, 3H), 2.87 (t, J = 7.2 Hz, 2H), 1.70–1.63 (m, 2H), 1.33–1.24
(m, 13H), 0.87 (t, J = 6.4 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 201.8,
171.5, 161.9, 137.5, 131.9, 129.7, 118.5, 111.8, 60.6, 55.3, 40.9,
40.2, 31.8, 29.4, 29.3, 29.2, 24.6, 22.6, 14.2, 14.0; IR (KBr) ν:
2925, 2854, 1736, 1675, 1604, 1569, 1463, 1367, 1315, 1254, 1160,
1132, 1032, 877, 816 cm–1; HRMS (quadrupole, EI):
calcd for C20H30O4 [M]+, 334.2144; found, 334.2147.

Ethyl 2-(2-Hexanoyl-4-methoxyphenyl)acetate
(5ea)
8.9 mg (15%); light yellow oil; 1H NMR (400
MHz, CDCl3): δ 7.26 (s, 1H), 7.16 (d, J = 8.4 Hz, 1H), 6.96 (dd, J = 8.4, 2.8 Hz, 1H),
4.15 (q, J = 7.2 Hz, 2H), 3.84 (s, 3H), 3.82 (s,
2H), 2.89 (t, J = 7.6 Hz, 2H), 1.72–1.64 (m,
2H), 1.35–1.31 (m, 4H), 1.25 (t, J = 7.2 Hz,
3H), 0.90 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 203.8, 171.9,
158.5, 138.8, 133.4, 126.0, 115.9, 115.5, 60.6, 55.5, 40.8, 39.1,
31.5, 23.9, 22.5, 14.2, 13.9; IR (KBr) ν: 2955, 2929, 2857,
1734, 1686, 1607, 1573, 1502, 1463, 1418, 1368, 1338, 1288, 1256,
1160, 1032, 984, 928, 875 cm–1; HRMS (quadrupole,
EI): calcd for C17H24O4 [M]+, 292.1675; found, 292.1673.

Ethyl 2-(2-Hexanoyl-6-methoxyphenyl)acetate
(5ea′)
22.3 mg (38%); light yellow oil; 1H NMR (400
MHz, CDCl3): δ 7.32 (t, J = 8.0
Hz, 1H), 7.27 (d, J = 7.2 Hz, 1H), 7.01 (d, J = 8.0 Hz, 1H), 4.14 (q, J = 7.2 Hz, 2H),
3.93 (s, 2H), 3.83 (s, 3H), 2.88 (t, J = 7.6 Hz,
2H), 1.71–1.64 (m, 2H), 1.34–1.30 (m, 4H), 1.25 (t, J = 6.8 Hz, 3H), 0.89 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ
204.8, 171.8, 158.2, 139.9, 127.8, 122.5, 120.3, 113.4, 60.5, 55.9,
41.6, 31.5, 31.4, 23.9, 22.5, 14.2, 13.9; IR (KBr) ν: 2955,
2932, 2871, 1734, 1685, 1580, 1459, 1439, 1409, 1367, 1335, 1265,
1205, 1158, 1030, 930, 883 cm–1; HRMS (quadrupole,
EI): calcd for C17H24O4 [M]+, 292.1675; found, 292.1674.

Ethyl 2-(2-Heptanoyl-4-methoxyphenyl)acetate
(5eb)
8.7 mg (14%); light yellow oil; 1H NMR (400
MHz, CDCl3): δ 7.26 (s, 1H), 7.16 (d, J = 8.4 Hz, 1H), 6.96 (dd, J = 8.4, 2.4 Hz, 1H),
4.13 (q, J = 7.2 Hz, 2H), 3.84 (s, 3H), 3.82 (s,
2H), 2.89 (t, J = 7.2 Hz, 2H), 1.71–1.64 (m,
2H), 1.38–1.28 (m, 6H), 1.25 (t, J = 7.2 Hz,
3H), 0.88 (t, J = 6.4 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 203.8, 171.9,
158.5, 138.8, 133.4, 126.0, 115.9, 115.5, 60.6, 55.5, 40.8, 39.1,
31.6, 28.9, 24.1, 22.5, 14.2, 14.0; IR (KBr) ν: 2955, 2930,
2857, 1734, 1685, 1608, 1574, 1501, 1463, 1418, 1367, 1337, 1254,
1213, 1159, 1031, 984, 929, 873 cm–1; HRMS (quadrupole,
EI): calcd for C18H26O4 [M]+, 306.1831; found, 306.1828.

Ethyl 2-(2-Heptanoyl-6-methoxyphenyl)acetate
(5eb′)
21.7 mg (35%); light yellow oil; 1H NMR (400
MHz, CDCl3): δ 7.32 (t, J = 8.0
Hz, 1H), 7.27 (d, J = 7.6 Hz, 1H), 7.01 (d, J = 8.0 Hz, 1H), 4.13 (q, J = 7.2 Hz, 2H),
3.93 (s, 2H), 3.83 (s, 3H), 2.88 (t, J = 7.6 Hz,
2H), 1.70–1.63 (m, 2H), 1.37–1.30 (m, 6H), 1.25 (t, J = 7.2 Hz, 3H), 0.87 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ
204.8, 171.8, 158.1, 139.9, 127.8, 122.5, 120.3, 113.4, 60.5, 55.9,
41.6, 31.6, 31.5, 28.9, 24.2, 22.5, 14.2, 14.0; IR (KBr) ν:
2954, 2930, 2857, 1734, 1685, 1580, 1459, 1439, 1367, 1335, 1265,
1238, 1205, 1159, 1030, 931 cm–1; HRMS (quadrupole,
EI): calcd for C18H26O4 [M]+, 306.1831; found, 306.1834.

Ethyl 2-(4-Methoxy-2-octanoylphenyl)acetate
(5ec)
8.4 mg (13%); light yellow oil; 1H NMR (400
MHz, CDCl3): δ 7.26 (br s, 1H), 7.16 (d, J = 8.0 Hz, 1H), 6.96 (dd, J = 8.0, 4.0
Hz, 1H), 4.12 (q, J = 8.0 Hz, 2H), 3.84 (s, 3H),
3.82 (s, 2H), 2.89 (t, J = 8.0 Hz, 2H), 1.69–1.64
(m, 2H), 1.33–1.23 (m, 11H), 0.87 (t, J =
8.0 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 203.8, 171.9, 158.5, 138.8, 133.4, 126.0, 115.9,
115.4, 60.6, 55.5, 40.8, 39.1, 31.7, 29.2, 29.1, 24.2, 22.6, 14.2,
14.0; IR (KBr) ν: 2954, 2925, 2854, 1735, 1686, 1608, 1574,
1501, 1464, 1418, 1368, 1252, 1213, 1159, 1032, 987, 928, 874 cm–1; HRMS (quadrupole, EI): calcd for C19H28O4 [M]+, 320.1988; found, 320.1990.

Ethyl 2-(2-Methoxy-6-octanoylphenyl)acetate (5ec′)
21.9 mg (34%); light yellow oil; 1H NMR (400
MHz, CDCl3): δ 7.32 (t, J = 8.0
Hz, 1H), 7.26 (d, J = 8.0 Hz, 1H), 7.01 (d, J = 8.0 Hz, 1H), 4.14 (q, J = 8.0 Hz, 2H),
3.93 (s, 2H), 3.83 (s, 3H), 2.88 (t, J = 8.0 Hz,
2H), 1.70–1.63 (m, 2H), 1.33–1.23 (m, 11H), 0.87 (t, J = 8.0 Hz, 3H); 13C{1H} NMR (100
MHz, CDCl3): δ 204.9, 171.8, 158.2, 139.9, 127.8,
122.6, 120.3, 113.3, 60.5, 55.9, 41.7, 31.7, 31.5, 29.2, 29.1, 24.3,
22.6, 14.2, 14.0; IR (KBr) ν: 2953, 2926, 2855, 1735, 1686,
1580, 1459, 1439, 1367, 1335, 1266, 1236, 1204, 1158, 1031, 1009,
930, 833 cm–1; HRMS (quadrupole, EI): calcd for
C19H28O4 [M]+, 320.1988;
found, 320.1989.

Ethyl 2-(4-Methoxy-2-nonanoylphenyl)acetate
(5ed)
8.7 mg (13%); light yellow oil; 1H NMR (400
MHz, CDCl3): δ 7.26 (s, 1H), 7.16 (d, J = 8.4 Hz, 1H), 6.96 (dd, J = 8.4, 2.8 Hz, 1H),
4.13 (q, J = 7.2 Hz, 2H), 3.84 (s, 3H), 3.82 (s,
2H), 2.89 (t, J = 7.6 Hz, 2H), 1.71–1.64 (m,
2H), 1.34–1.23 (m, 13H), 0.87 (t, J = 6.4
Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 203.8, 171.9, 158.5, 138.8, 133.4, 126.0, 115.9, 115.5,
60.6, 55.5, 40.8, 39.1, 31.8, 29.4, 29.3, 29.1, 24.2, 22.6, 14.2,
14.1; IR (KBr) ν: 2954, 2925, 2854, 1735, 1686, 1608, 1574,
1501, 1463, 1418, 1368, 1258, 1213, 1159, 1031, 985, 928, 874 cm–1; HRMS (quadrupole, EI): calcd for C20H30O4 [M]+, 334.2144; found, 334.2144.

Ethyl 2-(2-Methoxy-6-nonanoylphenyl)acetate (5ed′)
22.2 mg (33%); light yellow oil; 1H NMR (400
MHz, CDCl3): δ 7.32 (t, J = 8.0
Hz, 1H), 7.26 (d, J = 8.0 Hz, 1H), 7.01 (d, J = 8.0 Hz, 1H), 4.14 (q, J = 8.0 Hz, 2H),
3.93 (s, 2H), 3.83 (s, 3H), 2.88 (t, J = 8.0 Hz,
2H), 1.70–1.63 (m, 2H), 1.35–1.23 (m, 13H), 0.87 (t, J = 8.0 Hz, 3H); 13C{1H} NMR (100
MHz, CDCl3): δ 204.9, 171.8, 158.2, 139.9, 127.8,
122.5, 120.3, 113.3, 60.5, 55.9, 41.7, 31.8, 31.5, 29.4, 29.2, 29.1,
24.2, 22.6, 14.2, 14.0; IR (KBr) ν: 2952, 2926, 2853, 1737,
1606, 1596, 1489, 1462, 1425, 1340, 1304, 1262, 1207, 1148, 1098,
1053, 950, 827 cm–1; HRMS (quadrupole, EI): calcd
for C20H30O4 [M]+, 334.2144;
found, 334.2144.

Methyl 2-(2,3,4-Trimethoxy-6-octanoylphenyl)acetate
(6aa)
29.7 mg (39%); yellowish oil; 1H NMR (400 MHz,
CDCl3): δ 7.04 (s, 1H), 3.91 (s, 3H), 3.90 (s, 3H),
3.89 (s, 2H), 3.83 (s, 3H), 3.68 (s, 3H), 2.85 (t, J = 7.2 Hz, 2H), 1.70–1.63 (m, 2H), 1.32–1.24 (m, 8H),
0.86 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 202.9, 172.5, 152.8,
151.8, 145.1, 133.4, 121.7, 108.5, 61.0, 60.7, 56.2, 51.8, 40.9, 31.7,
31.6, 29.2, 29.1, 24.3, 22.5, 14.0; IR (KBr) ν: 2929, 2854,
1738, 1682, 1593, 1568, 1495, 1454, 1403, 1333, 1290, 1194, 1164,
1136, 1115, 1048, 1004, 962, 919, 841 cm–1; HRMS
(quadrupole, EI): calcd for C20H30O6 [M]+, 366.2042; found, 366.2045.

Isopropyl
2-(2,3,4-Trimethoxy-6-octanoylphenyl)acetate (6ab)
44.3 mg (56%); yellow oil; 1H NMR
(400 MHz, CDCl3): δ 7.04 (s, 1H), 5.05–4.99
(m, 1H), 3.93 (s, 3H), 3.92 (s, 3H), 3.88 (s, 2H), 3.85 (s, 3H), 2.87
(t, J = 7.6 Hz, 2H), 1.72–1.65 (m, 2H), 1.35–1.25
(m, 8H), 1.27 (s, 3H), 1.25 (s, 3H), 0.89 (t, J =
6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 203.6, 171.5, 152.8, 151.7, 144.9, 133.7, 121.8,
108.4, 67.8, 61.0, 60.7, 56.2, 41.1, 32.1, 31.6, 29.2, 29.1, 24.3,
22.5, 21.8, 14.0; IR (KBr) ν: 2929, 2854, 1731, 1683, 1593,
1568, 1495, 1454, 1403, 1325, 1289, 1229, 1173, 1136, 1108, 1047,
1005, 970, 919, 830 cm–1; HRMS (quadrupole, EI):
calcd for C22H34O6 [M]+, 394.2355; found, 394.2358.

Butyl 2-(2,3,4-Trimethoxy-6-octanoylphenyl)acetate
(6ac)
53.1 mg (65%); yellowish oil; 1H NMR (400 MHz,
CDCl3): δ 7.02 (s, 1H), 4.08 (t, J = 6.8 Hz, 2H), 3.90 (s, 3H), 3.89 (s, 3H), 3.88 (s, 2H), 3.82 (s,
3H), 2.85 (t, J = 7.2 Hz, 2H), 1.68–1.57 (m,
4H), 1.41–1.24 (m, 10H), 0.91 (t, J = 7.2
Hz, 3H), 0.86 (t, J = 7.2 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 203.0, 172.1,
152.8, 151.8, 145.0, 133.6, 121.8, 108.4, 64.5, 61.0, 60.7, 56.2,
41.1, 31.8, 31.6, 30.6, 29.2, 29.1, 24.3, 22.5, 19.1, 14.0, 13.6;
IR (KBr) ν: 2955, 2930, 2855, 1735, 1683, 1593, 1568, 1495,
1454, 1403, 1332, 1289, 1164, 1136, 1115, 1047, 1005, 967, 918, 837
cm–1; HRMS (quadrupole, EI): calcd for C23H36O6 [M]+, 408.2512; found, 408.2509.

Benzyl 2-(2,3,4-Trimethoxy-6-octanoylphenyl)acetate (6ad)
45.1 mg (51%); light yellow solid; mp = 64.8–66.7
°C; 1H NMR (400 MHz, CDCl3): δ 7.37–7.29
(m, 5H), 7.04 (s, 1H), 5.15 (s, 2H), 3.97 (s, 2H), 3.91 (s, 6H), 3.79
(s, 3H), 2.84 (t, J = 7.2 Hz, 2H), 1.69–1.61
(m, 2H), 1.31–1.25 (m, 8H), 0.88 (t, J = 6.4
Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 202.9, 171.9, 152.8, 151.7, 145.1, 136.2, 133.5, 128.3,
128.1, 127.9, 121.6, 108.4, 66.3, 61.0, 60.7, 56.2, 41.0, 31.8, 31.6,
29.2, 29.1, 24.3, 22.6, 14.0; IR (KBr) ν: 2955, 2930, 2855,
1735, 1683, 1593, 1568, 1495, 1454, 1403, 1333, 1165, 1136, 1115,
1048, 1006, 968, 919, 834 cm–1; HRMS (quadrupole,
EI): calcd for C26H34O6 [M]+, 442.2355; found, 442.2354.

Experimental Procedure
and Characterization Data for the Synthesis
of Phomopsin C (7a)
To an oven-dried sealed
tube charged with ethyl 2-(3,5-dimethoxy-2-octanoylphenyl)acetate
(5cc) (70.1 mg, 0.2 mmol, 100 mol %) in CH2Cl2 (1 mL) was added boron tribromide (1 M solution in
dichloromethane, 0.8 mL, 0.8 mmol, 400 mol %) under argon at −78
°C. The reaction mixture was allowed to stir for 2 h at 0 °C.
The reaction mixture was cooled to room temperature, quenched with
H2O and saturated NaHCO3 solution to make pH
7 of the reaction mixture, and then extracted with EtOAc (3 ×
20 mL). The organic layer was dried over MgSO4, filtered,
and concentrated in vacuo. The residue was purified by flash column
chromatography (n-hexanes/EtOAc = 5:1) to afford 7a (51.1 mg) in 76% yield.

Ethyl 2-(3-Hydroxy-5-methoxy-2-octanoylphenyl)acetate
(7a)
51.1 mg (76%); brown solid; mp 75.6–77.8
°C; 1H NMR (400 MHz, CDCl3): δ 12.4
(s, 1H), 6.36 (d, J = 2.0 Hz, 1H), 6.31 (d, J = 2.0 Hz, 1H), 4.17 (q, J = 7.2 Hz, 2H),
3.84 (s, 2H), 3.79 (s, 3H), 2.82 (t, J = 7.6 Hz,
2H), 1.72–1.65 (m, 2H), 1.30–1.23 (m, 8H), 1.25 (t, J = 7.2 Hz, 3H), 0.86 (t, J = 7.2 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ
206.5, 170.8, 165.1, 163.6, 136.2, 115.9, 112.5, 100.4, 61.3, 55.3,
43.2, 41.9, 31.6, 29.1, 29.0, 24.9, 22.5, 14.1, 14.0; IR (KBr) ν:
3228, 2954, 2925, 2854, 1736, 1710, 1608, 1588, 1464, 1438, 1368,
1305, 1197, 1153, 1022, 962, 844 cm–1; HRMS (orbitrap,
ESI): calcd for C19H28O5 [M + H]+, 336.1937; found, 336.1939.

Experimental Procedure
and Characterization Data for the Synthesis
of Carboxylic Acid (7b)
To an oven-dried sealed
tube charged with 2-(3,5-dimethoxy-2-octanoylphenyl)acetate (5cc) (70.1 mg, 0.2 mmol, 100 mol %) were added 1 M NaOH (1
mL) and THF (1 mL) under air at room temperature. The reaction mixture
was allowed to stir for 14 h at room temperature. The reaction mixture
was quenched with 1 M HCl (1 mL) to make pH 7 and extracted with CH2Cl2 (3 × 20 mL). The organic layer was dried
over MgSO4, filtered, and concentrated in vacuo. The residue
was purified by flash column chromatography (n-hexanes/EtOAc
= 1:2) to afford 7b (46.3 mg) in 72% yield.

2-(3,5-Dimethoxy-2-octanoylphenyl)acetic
Acid (7b)
46.3 mg (72%); light brown solid;
mp 80.8–82.3
°C; 1H NMR (400 MHz, CDCl3): δ 6.48
(d, J = 1.6 Hz, 1H), 6.40 (d, J =
2.0 Hz, 1H), 3.84 (s, 3H), 3.82 (s, 3H), 3.51 (s, 2H), 2.91 (t, J = 7.6 Hz, 2H), 1.68–1.61 (m, 2H), 1.28–1.26
(m, 8H), 0.86 (t, J = 6.8 Hz, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 210.1, 172.1,
162.6, 159.9, 135.4, 122.6, 107.5, 98.2, 55.7, 55.6, 44.2, 41.4, 31.6,
29.3, 29.0, 24.7, 22.5, 14.0; IR (KBr) ν: 2925, 2853, 1738,
1711, 1600, 1580, 1457, 1423, 1324, 1290, 1203, 1153, 1084, 1059,
950, 835 cm–1; HRMS (orbitrap, ESI): calcd for C18H26O5 [M + H]+, 322.1780;
found, 322.1779.

Experimental Procedure and Characterization
Data for the Synthesis
of 1-Heptyl-6,8-dimethoxyisochroman (7c)
To
an oven-dried sealed tube charged with 2-(3,5-dimethoxy-2-octanoylphenyl)acetate
(5cc) (70.1 mg, 0.2 mmol, 100 mol %) were added NaBH4 (15.1 mg, 0.4 mmol, 200 mol %) and EtOH (1 mL) under air
at room temperature. The reaction mixture was allowed to stir for
4 h at 60 °C. The reaction mixture was cooled to room temperature,
quenched with H2O and saturated NH4Cl solution
to make pH 7 of reaction mixture, and then extracted with CH2Cl2 (3 × 20 mL). The organic layer was dried over
MgSO4, filtered, and concentrated in vacuo. The residue
was purified by flash column chromatography (n-hexanes/EtOAc
= 15:1) to afford 7c (23.4 mg) in 40% yield.

1-Heptyl-6,8-dimethoxyisochroman
(7c)
23.4 mg (40%); yellowish oil; 1H NMR (400 MHz, CD3OD): δ 6.29 (s, 1H), 6.24 (s,
1H), 4.80 (dd, J = 8.8, 2.0 Hz, 1H), 4.02–3.96
(m, 1H), 3.78 (s,
3H), 3.77 (s, 3H), 3.76–3.72 (m, 1H), 2.84–2.76 (m,
1H), 2.69 (dt, J = 16.4, 4.8 Hz, 1H), 1.86–1.69
(m, 2H), 1.46–1.43 (m, 2H), 1.35–1.26 (m, 8H), 0.88
(t, J = 6.4 Hz, 3H); 13C{1H}
NMR (100 MHz, CDCl3): δ 158.7, 156.7, 135.6, 120.1,
104.1, 96.5, 72.0, 59.5, 55.2, 55.1, 33.2, 31.9, 29.5, 29.4, 29.3,
25.8, 22.7, 14.1; IR (KBr) ν: 2952, 2923, 2853, 1736, 1605,
1595, 1489, 1463, 1425, 1340, 1304, 1261, 1207, 1148, 1098, 1054,
951, 827 cm–1; HRMS (orbitrap, ESI): calcd for C18H28O3 [M + H]+, 292.2038;
found, 292.2040.

5-(6-Heptanoyl-2,3,4-trimethoxyphenyl)-2,2-dimethyl-1,3-dioxane-4,6-dione
(8ab)
57.4 mg (68%); yellowish oil; 1H NMR (400 MHz, CDCl3): δ 6.73 (s, 1H), 5.24 (s,
1H), 3.97 (s, 3H), 3.91 (s, 3H), 3.86 (s, 3H), 2.40–2.34 (m,
2H), 1.82 (s, 3H), 1.79 (s, 3H), 1.55 (m, 2H), 1.46 (m, 2H), 1.33
(m, 4H), 0.94–0.86 (m, 3H); 13C NMR (100 MHz, CDCl3): δ 207.7, 164.9, 161.3, 159.4, 154.6, 145.6, 124.6,
113.3, 106.1, 102.2, 67.1, 61.2, 60.9, 56.1, 46.5, 31.5, 28.8, 28.2,
27.3, 24.9, 22.5, 14.0; IR (KBr) ν: 2922, 2851, 1734, 1603,
1596, 1490, 1462, 1341, 1303, 1260, 1208, 1149, 1099, 951, 830 cm–1; HRMS (quadrupole, EI): calcd for C20H30O8 [M]+, 422.1941; found, 422.1939.

In Vitro Assay of Synthetic Compounds on p-AMPK Activation
HepG2 cells were treated with the compounds for 4 h, and the p-AMPK
expression was determined by the western blotting analysis. The HepG2
hepatocytes were obtained from the American Type Culture Collection
(ATCC, USA). The HepG2 cells were cultured in Dulbecco’s modified
Eagle’s medium containing glucose (Invitrogen, USA), supplemented
with 10% (v/v) fetal bovine serum (Gibco BRL, USA). After treatment
with compounds for 4 h, HepG2 cells were collected and washed with
cold PBS. The harvested cells were then lysed on ice for 30 min in
100 μL lysis buffer [120 mM NaCl, 40 mM Tris (pH 8.0), 0.1%
Nonidet P-40] and centrifuged at 10 000g for
30 min. The supernatants were collected from the lysates and the protein
concentrations were determined using the protein assay kit (Pierce,
Rockford, IL). Aliquots of the lysates (20 μg protein) were
boiled for 5 min and electrophoresed on 10% SDS-polyacrylamide gels.
Proteins in the gels were transferred to nitrocellulose membranes,
which were then incubated with p-AMPK antibody (Cell Signaling Technology,
Beverly, MA) or mouse monoclonal β-actin antibody (Sigma-Aldrich,
St. Louis, MO). The membranes were further incubated with secondary
antimouse or antirabbit antibodies. Finally, protein bands were detected
using an enhanced chemiluminescence western blotting detection kit
(Pierce Biotechnology, Rockford, IL).

Antidiabetic Evaluation
of 5ac and 5cd Using Type 2 Diabete-Induced
Animal Models
Rats were fasted
overnight and were administered with a single intraperitoneal injection
with STZ (25 mg/kg/body weight) in 0.1 M citrate buffer (pH 4.5).
TMPA (5ac) and 5cd were, respectively, dissolved
in DMSO into a final concentration of 1 M and then dissolved in 5.0%
(v/v) Tween-80 in 0.9% (w/v) saline. One group of rat was injected
intraperitoneally with TMPA (5ac) daily at a dose of
25 mg/kg/body weight for 7 days. One group of rat was injected intraperitoneally
with 5cd daily at a dose of 25 mg/kg/body weight for
7 days. The other group was injected with metformin as a positive
control (250 mg/kg/body weight dissolved in normal saline). Before
the blood glucose measurement, rats were fasted for 12 h. The blood
glucose level of rat was analyzed in every alternative days using
OneTouch Ultra glucometer.

Supporting Information Available
The Supporting Information
is
available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.8b00179.Immunoblot assay
of synthetic compounds on AMPK activation,
and 1H and 13C NMR copies of all products (PDF)



Supplementary Material
ao8b00179_si_001.pdf

 Author Contributions
∥ S.H.L. and A.K. equally contributed.

The authors
declare no competing financial interest.

Acknowledgments
This work was supported by the National Research
Foundation of Korea (NRF) grant funded by the Korea government (MSIP)
(nos. 2016R1A4A1011189, 2016R1C1B2014895, and 2017R1A2B2004786).
==== Refs
References
For selected reviews, see:

a Oh D. Y. ; Olefsky J. M. 
G protein-coupled
receptors as targets for anti-diabetic
therapeutics . Nat. Rev. Drug Discovery 
2016 , 15 , 161 –172 . 10.1038/nrd.2015.4 .26822831  b Sterrett J. J. ; Bragg S. ; Weart C. W. 
Type 2 diabetes medication review . Am. J. Med. Sci. 
2016 , 351 , 342 –355 . 10.1016/j.amjms.2016.01.019 .27079339  c Klil-Drori A. J. ; Azoulay L. ; Pollak M. N. 
Cancer,
obesity, diabetes, and antidiabetic drugs: is the fog clearing? . Nat. Rev. Clin. Oncol. 
2017 , 14 , 85 –99 . 10.1038/nrclinonc.2016.120 .27502359 
For selected reviews, see:

a Krentz A. J. ; Bailey C. J. 
Oral antidiabetic agents: current
role in type 2 diabetes
mellitus . Drugs 
2005 , 65 , 385 –411 . 10.2165/00003495-200565030-00005 .15669880  b Stein S. A. ; Lamos E. M. ; Davis S. N. 
A review of the
efficacy and safety of oral antidiabetic drugs . Expert Opin. Drug Saf. 
2013 , 12 , 153 –175 . 10.1517/14740338.2013.752813 .23241069  c He Z.-X. ; Zhou Z.-W. ; Yang Y. ; Yang T. ; Pan S.-Y. ; Qiu J.-X. ; Zhou S.-F. 
Overview of clinically
approved oral antidiabetic agents for the treatment of type 2 diabetes
mellitus . Clin. Exp. Pharmacol. Physiol. 
2015 , 42 , 125 –138 . 10.1111/1440-1681.12332 .25360831  d Tahrani A. A. ; Barnett A. H. ; Bailey C. J. 
Pharmacology and therapeutic implications
of current drugs for type 2 diabetes mellitus . Nat. Rev. Endocrinol. 
2016 , 12 , 566 –592 . 10.1038/nrendo.2016.86 .27339889 
For selected examples,
see:

a Zhou G. ; Myers R. ; Li Y. ; Chen Y. ; Shen X. ; Fenyk-Melody J. ; Wu M. ; Ventre J. ; Doebber T. ; Fujii N. ; Musi N. ; Hirshman M. F. ; Goodyear L. J. ; Moller D. E. 
Role of AMP-activated protein kinase
in mechanism of
metformin action . J. Clin. Invest. 
2001 , 108 , 1167 –1174 . 10.1172/jci200113505 .11602624  b Zhang L. ; He H. ; Balschi J. A. 
Metformin and phenformin activate AMP-activated protein
kinase in the heart by increasing cytosolic AMP concentration . Am. J. Physiol.: Heart Circ. Physiol. 
2007 , 293 , H457 –H466 . 10.1152/ajpheart.00002.2007 .17369473  c Kim Y. D. ; Park K.-G. ; Lee Y.-S. ; Park Y.-Y. ; Kim D.-K. ; Nedumaran B. ; Jang W. G. ; Cho W.-J. ; Ha J. ; Lee I.-K. ; Lee C.-H. ; Choi H.-S. 
Metformin inhibits
hepatic gluconeogenesis through AMP-activated protein kinase-dependent
regulation of the orphan nuclear receptor SHP . Diabetes 
2008 , 57 , 306 –314 . 10.2337/db07-0381 .17909097 
Brady S. F. ; Wagenaar M. M. ; Singh M. P. ; Janso J. E. ; Clardy J. 
The cytosporones,
new octaketide antibiotics isolated from an endophytic fungus . Org. Lett. 
2000 , 2 , 4043 –4046 . 10.1021/ol006680s .11112639 
a Zhan Y. ; Du X. ; Chen H. ; Liu J. ; Zhao B. ; Huang D. ; Li G. ; Xu Q. ; Zhang M. ; Weimer B. C. ; Chen D. ; Cheng Z. ; Zhang L. ; Li Q. ; Li S. ; Zheng Z. ; Song S. ; Huang Y. ; Ye Z. ; Su W. ; Lin S.-C. ; Shen Y. ; Wu Q. 
Cytosporone B is an
agonist for nuclear orphan receptor Nur77 . Nat.
Chem. Biol. 
2008 , 4 , 548 –556 . 10.1038/nchembio.106 .18690216  b Liu J.-j. ; Zeng H.-n. ; Zhang L.-r. ; Zhan Y.-y. ; Chen Y. ; Wang Y. ; Wang J. ; Xiang S.-h. ; Liu W.-j. ; Wang W.-j. ; Chen H.-z. ; Shen Y.-m. ; Su W.-j. ; Huang P.-q. ; Zhang H.-k. ; Wu Q. 
A unique pharmacophore
for activation of the nuclear orphan receptor Nur77 in vivo and in
vitro . Cancer Res. 
2010 , 70 , 3628 –3637 . 10.1158/0008-5472.can-09-3160 .20388790 
a Zhan Y.-y. ; Chen Y. ; Zhang Q. ; Zhuang J.-j. ; Tian M. ; Chen H.-z. ; Zhang L.-r. ; Zhang H.-k. ; He J.-p. ; Wang W.-j. ; Wu R. ; Wang Y. ; Shi C. ; Yang K. ; Li A.-z. ; Xin Y.-z. ; Li T. Y. ; Yang J. Y. ; Zheng Z.-h. ; Yu C.-d. ; Lin S.-C. ; Chang C. ; Huang P.-q. ; Lin T. ; Wu Q. 
The orphan
nuclear receptor Nur77 regulates LKB1 localization and activates AMPK . Nat. Chem. Biol. 
2012 , 8 , 897 –904 . 10.1038/nchembio.1069 .22983157  b Sun W. ; Yuan Y. ; Lee B. ; Jun H.-S. ; Shin D. ; Seo S.-Y. 
Short synthesis of the antidiabetic
octaketide ethyl 2-(2,3,4-trimethoxy-6-octanoylphenyl)acetate . Synlett 
2018 , 29 , 326 –329 . 10.1055/s-0036-1592062 .
For recent reviews, see:

a Mishra N. K. ; Sharma S. ; Park J. ; Han S. ; Kim I. S. 
Recent
advances in catalytic C(sp2)–H allylation reactions . ACS Catal. 
2017 , 7 , 2821 –2847 . 10.1021/acscatal.7b00159 . b Wang F. ; Yu S. ; Li X. 
Transition metal-catalysed
couplings between arenes and strained or reactive rings: combination
of C–H activation and ring scission . Chem. Soc. Rev. 
2016 , 45 , 6462 –6477 . 10.1039/c6cs00371k .27711636  c Li S.-S. ; Qin L. ; Dong L. 
Rhodium-catalyzed C–C
coupling reactions via double C–H activation . Org. Biomol. Chem. 
2016 , 14 , 4554 –4570 . 10.1039/c6ob00209a .27099126  d Rao W.-H. ; Shi B.-F. 
Recent advances
in copper-mediated chelation-assisted functionalization of unactivated
C–H bonds . Org. Chem. Front. 
2016 , 3 , 1028 –1047 . 10.1039/c6qo00156d .
Chan W.-W. ; Lo S.-F. ; Zhou Z. ; Yu W.-Y. 
Rh-catalyzed intermolecular
carbenoid functionalization of aromatic C–H bonds by α-diazomalonates . J. Am. Chem. Soc. 
2012 , 134 , 13565 –13568 . 10.1021/ja305771y .22860697 
For selected reviews, see:

a Davies H. M.
L. ; Beckwith R. E. J. 
Catalytic
enantioselective C–H
activation by means of metal-carbenoid-induced C–H insertion . Chem. Rev. 
2003 , 103 , 2861 –2904 . 10.1021/cr0200217 .12914484  b Hu F. ; Xia Y. ; Ma C. ; Zhang Y. ; Wang J. 
C–H bond functionalization based on metal carbene migratory
insertion . Chem. Commun. 
2015 , 51 , 7986 –7995 . 10.1039/c5cc00497g . c For selected examples,
see: Hu F. ; Xia Y. ; Ye F. ; Liu Z. ; Ma C. ; Zhang Y. ; Wang J. 
Rhodium(III)-catalyzed
ortho alkenylation of N-phenoxyacetamides with N-tosylhydrazones or diazoesters through C–H activation . Angew. Chem., Int. Ed. 
2014 , 53 , 1364 –1367 . 10.1002/anie.201309650 . d Mishra N. K. ; Park J. ; Sharma S. ; Han S. ; Kim M. ; Shin Y. ; Jang J. ; Kwak J. H. ; Jung Y. H. ; Kim I. S. 
Direct access to isoindolines through
tandem Rh(III)-catalyzed alkenylation and cyclization of N-benzyltriflamides . Chem. Commun. 
2014 , 50 , 2350 –2352 . 10.1039/c3cc49486a . e Ai W. ; Yang X. ; Wu Y. ; Wang X. ; Li Y. ; Yang Y. ; Zhou B. 
Rhodium(III)- and iridium(III)-catalyzed
C7 alkylation of indolines with diazo compounds . Chem.—Eur. J. 
2014 , 20 , 17653 –17657 . 10.1002/chem.201405077 .25359110  f Jeong J. ; Patel P. ; Hwang H. ; Chang S. 
Rhodium(III)-catalyzed C–C bond formation of quinoline N-oxides at the C-8 position under mild conditions . Org. Lett. 
2014 , 16 , 4598 –4601 . 10.1021/ol502173d .25141216  g Xia Y. ; Liu Z. ; Feng S. ; Zhang Y. ; Wang J. 
Ir(III)-catalyzed aromatic C–H bond functionalization via
metal carbene migratory insertion . J. Org. Chem. 
2015 , 80 , 223 –236 . 10.1021/jo5023102 .25437770 
a Shi J. ; Yan Y. ; Li Q. ; Xu H. E. ; Yi W. 
Rhodium(III)-catalyzed C2-selective
carbenoid functionalization and subsequent C7-alkenylation of indoles . Chem. Commun. 
2014 , 50 , 6483 –6486 . 10.1039/c4cc01593b . b Son J.-Y. ; Kim S. ; Jeon W. H. ; Lee P. H. 
Synthesis of cinnolin-3(2H)-one derivatives
from Rh-catalyzed reaction of azobenzenes with diazotized meldrum’s
acid . Org. Lett. 
2015 , 17 , 2518 –2521 . 10.1021/acs.orglett.5b01052 .25932946  c Sharma S. ; Han S. H. ; Han S. ; Ji W. ; Oh J. ; Lee S.-Y. ; Oh J. S. ; Jung Y. H. ; Kim I. S. 
Rh(III)-catalyzed
direct coupling of azobenzenes with α-diazo esters: facile synthesis
of cinnolin-3(2H)-ones . Org.
Lett. 
2015 , 17 , 2852 –2855 . 10.1021/acs.orglett.5b01298 .25990571  d Shi J. ; Zhou J. ; Yan Y. ; Jia J. ; Liu X. ; Song H. ; Xu H. E. ; Yi W. 
One-pot cascade synthesis
of N-methoxyisoquinolinediones via Rh(III)-catalyzed carbenoid insertion C–H activation/cyclization . Chem. Commun. 
2015 , 51 , 668 –671 . 10.1039/c4cc08407a .
a Jeon M. ; Mishra N. K. ; De U. ; Sharma S. ; Oh Y. ; Choi M. ; Jo H. ; Sachan R. ; Kim H. S. ; Kim I. S. 
Rh(III)-catalyzed
C–H functionalization of indolines with readily accessible
amidating reagent: synthesis and anticancer evaluation . J. Org. Chem. 
2016 , 81 , 9878 –9885 . 10.1021/acs.joc.6b02020 .27680096  b Han S.
H. ; Kim S. ; De U. ; Mishra N. K. ; Park J. ; Sharma S. ; Kwak J. H. ; Han S. ; Kim H. S. ; Kim I. S. 
Synthesis of succinimide-containing
chromones, naphthoquinones, and xanthones under Rh(III) catalysis:
evaluation of anticancer activity . J. Org. Chem. 
2016 , 81 , 12416 –12425 . 10.1021/acs.joc.6b02577 .27978756  c Sharma S. ; Oh Y. ; Mishra N. K. ; De U. ; Jo H. ; Sachan R. ; Kim H. S. ; Jung Y. H. ; Kim I. S. 
Rhodium-catalyzed
[3+2] annulation of cyclic N-acyl ketimines with
activated olefins: anticancer activity of spiroisoindolinones . J. Org. Chem. 
2017 , 82 , 3359 –3367 . 10.1021/acs.joc.6b02708 .28385021  d Jeong T. ; Lee S. H. ; Mishra N. K. ; De U. ; Park J. ; Dey P. ; Kwak J. H. ; Jung Y. H. ; Kim H. S. ; Kim I. S. 
Synthesis
and cytotoxic evaluation of N-aroylureas through
rhodium(III)-catalyzed C–H functionalization of indolines with
isocyanates . Adv. Synth. Catal. 
2017 , 359 , 2329 –2336 . 10.1002/adsc.201700311 . e Jeon M. ; Park J. ; Dey P. ; Oh Y. ; Oh H. ; Han S. ; Um S. H. ; Kim H. S. ; Mishra N. K. ; Kim I. S. 
Site-selective rhodium(III)-catalyzed C–H amination
of 7-azaindoles with anthranils: synthesis and anticancer evaluation . Adv. Synth. Catal. 
2017 , 359 , 3471 –3478 . 10.1002/adsc.201700800 . f Oh Y. ; Jang Y. J. ; Jeon M. ; Kim H. S. ; Kwak J. H. ; Chung K. H. ; Pyo S. ; Jung Y. H. ; Kim I. S. 
Total synthesis and anti-inflammatory
evaluation of penchinone A and its structural analogues . J. Org. Chem. 
2017 , 82 , 11566 –11572 . 10.1021/acs.joc.7b02212 .29019238 
a Fujita K.-i. ; Asai C. ; Yamaguchi T. ; Hanasaka F. ; Yamaguchi R. 
Direct β-alkylation of secondary
alcohols with primary alcohols catalyzed by a Cp*Ir complex . Org. Lett. 
2005 , 7 , 4017 –4019 . 10.1021/ol051517o .16119956  b Li F. ; Ma J. ; Wang N. 
α-Alkylation
of ketones with primary alcohols catalyzed by a Cp*Ir complex bearing
a functional bipyridonate ligand . J. Org. Chem. 
2014 , 79 , 10447 –10455 . 10.1021/jo502051d .25313673  c Wang D. ; Zhao K. ; Xu C. ; Miao H. ; Ding Y. 
Synthesis, structures of benzoxazolyl iridium(III) complexes, and
applications on C–C and C–N bond formation reactions
under solvent-free conditions: catalytic activity enhanced by noncoordinating
anion without silver effect . ACS Catal. 
2014 , 4 , 3910 –3918 . 10.1021/cs5009909 .
a Huang Z. ; Cai X. ; Shao C. ; She Z. ; Xia X. ; Chen Y. ; Yang J. ; Zhou S. ; Lin Y. 
Chemistry and weak antimicrobial activities of phomopsins produced
by mangrove endophytic fungus Phomopsis sp. ZSU-H76 . Phytochemistry 
2008 , 69 , 1604 –1608 . 10.1016/j.phytochem.2008.02.002 .18343465  b Yoshida H. ; Morishita T. ; Ohshita J. 
An aryne route to cytosporone B and
phomopsin C . Chem. Lett. 
2010 , 39 , 508 –509 . 10.1246/cl.2010.508 .
Best D. ; Jean M. ; van de Weghe P. 
Modular synthesis of arylacetic acid
esters, thioesters, and amides from aryl ethers via Rh(II)-catalyzed
diazo arylation . J. Org. Chem. 
2016 , 81 , 7760 –7770 . 10.1021/acs.joc.6b01426 .27465907 
a Kurth-Kraczek E. J. ; Hirshman M. F. ; Goodyear L. J. ; Winder W. W. 
5’ AMP-activated protein kinase activation causes
GLUT4 translocation in skeletal muscle . Diabetes 
1999 , 48 , 1667 –1671 . 10.2337/diabetes.48.8.1667 .10426389  b Hayashi T. ; Hirshman M. F. ; Fujii N. ; Habinowski S. A. ; Witters L. A. ; Goodyear L. J. 
Metabolic stress and altered glucose
transport: activation of AMP-activated protein kinase as a unifying
coupling mechanism . Diabetes 
2000 , 49 , 527 –531 . 10.2337/diabetes.49.4.527 .10871188 
Ye J.-M. ; Stanley M. H. 
Strategies for the discovery and
development of anti-diabetic
drugs from the natural products of traditional medicines . J. Pharm. Pharm. Sci. 
2013 , 16 , 207 –216 . 10.18433/j3t60g .23958190

